MOTS-C and Female Biology Research: Sex-Dimorphic Mitochondrial Peptide Biology, Oestrogen Crosstalk and Female Metabolic Mechanisms UK 2026

This article is intended for researchers and laboratory scientists. MOTS-C is a research peptide supplied for laboratory and in vitro use only. All findings described are from preclinical models or early-phase studies. This content does not constitute medical advice.

Introduction: Why MOTS-C Research Has a Female Biology Problem

MOTS-C (mitochondrial open reading frame of the 12S rRNA-c) was identified as a mitochondrial-encoded peptide in 2015, but the majority of early mechanistic studies used male rodent models or sex-unspecified cell lines. As the field matured, a striking pattern emerged: MOTS-C circulating levels differ substantially between males and females, decline sharply with female reproductive ageing (menopause), and interact with oestrogen signalling in ways that make the mitochondrial peptide uniquely relevant to female metabolic biology. This article examines the sex-dimorphic aspects of MOTS-C biology — MOTS-C and oestrogen crosstalk, female-specific AMPK activation patterns, the perimenopausal MOTS-C decline, and the implications for research into female metabolic syndrome, bone biology, and cardiovascular risk.

MOTS-C Plasma Levels Across the Female Lifespan

The sex-dimorphic distribution of MOTS-C was first characterised in human cohort studies comparing plasma concentrations across age and reproductive status. In premenopausal women, circulating MOTS-C levels are broadly comparable to age-matched men, but the decline trajectory differs substantially. Males show a gradual, linear decline in MOTS-C with advancing age — loosely paralleling testosterone decline. Females show a more precipitous drop coinciding with perimenopause, suggesting that ovarian function actively supports MOTS-C production or secretion.

Luciferase-linked radioligand competition assays and ELISA-based quantification in prospective cohorts confirm that postmenopausal women have significantly lower MOTS-C than premenopausal women of the same BMI and activity level. This gap is partially closed by hormone replacement therapy (HRT), implicating oestradiol (E2) in MOTS-C regulation. The MOTS-C gene resides within mitochondrial DNA at the 12S rRNA locus, meaning its expression is subject to mitochondrial transcriptional regulation — and mitochondrial biogenesis is itself oestrogen-responsive through oestrogen receptor β (ERβ) acting on nuclear-encoded mitochondrial gene promoters including TFAM and NRF1.

Oestrogen Receptor β and Mitochondrial MOTS-C Regulation

ERβ is the predominant ER isoform in mitochondria, where it colocalises with the mitochondrial import machinery and regulates mt-transcription factors. E2–ERβ signalling upregulates PGC-1α, which drives NRF1/TFAM-dependent mitochondrial biogenesis and — as a downstream consequence — increases MOTS-C precursor 12S rRNA transcription. Chromatin immunoprecipitation studies in MCF-7 cells and primary human granulosa cells demonstrate E2-dependent recruitment of ERβ to TFAM promoter oestrogen response elements (EREs), with downstream increases in 12S rRNA steady-state levels within 6–8 hours. The MOTS-C ORF within the 12S rRNA precursor is processed post-transcriptionally by mitochondrial ribosomes, so any increase in 12S rRNA abundance produces a proportionate increase in translatable MOTS-C template.

This regulatory axis means that the E2 → ERβ → PGC-1α → TFAM → 12S rRNA → MOTS-C cascade represents a direct mechanistic link between ovarian function and mitochondrial peptide output. Selective ERβ agonists (diarylpropionitrile, DPN; 8β-VE2) phenocopy E2 in restoring MOTS-C production in ovariectomised (OVX) mice, while ERα-selective agonists (propyl pyrazole triol, PPT) are less effective — establishing isoform specificity. ICI 182,780 (fulvestrant) suppresses MOTS-C production in cycling females but not in males at equivalent doses, further confirming oestrogen dependence is female-specific at physiological concentrations.

MOTS-C–AMPK Crosstalk in Female Metabolic Tissue

MOTS-C activates AMP-activated protein kinase (AMPK) via MTHFD2-driven one-carbon metabolite flux — specifically through AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) accumulation and direct AMPK-α Thr-172 phosphorylation. In females, the threshold for AMPK activation by MOTS-C appears lower in skeletal muscle and adipose tissue compared to males, which may partly reflect the lower basal mitochondrial oxidative capacity in oestrogen-deficient states creating a greater AMPK-responsive energetic deficit. Compound C (dorsomorphin) AMPK inhibition ablates MOTS-C metabolic effects in both sexes, confirming pathway essentiality.

In female-specific metabolic contexts, MOTS-C–AMPK signalling targets include: hormone-sensitive lipase (HSL) Ser-565 phosphorylation inhibiting lipolysis in visceral adipocytes, ACC Ser-79 suppression reducing malonyl-CoA and enabling CPT-1-dependent fatty acid oxidation in skeletal muscle, and PGC-1α Ser-177/Thr-177 phosphorylation driving GLUT4 translocation and insulin-sensitisation in oestrogen-deficient muscle. The insulin-sensitising effect of MOTS-C in OVX mouse skeletal muscle (measured by euglycaemic-hyperinsulinaemic clamp glucose infusion rate, GIR) is substantially larger than in sham-operated controls, suggesting oestrogen deficiency creates a permissive state for MOTS-C metabolic rescue.

Glucose Uptake and GLUT4 Regulation

Primary human skeletal muscle cells (HSMCs) derived from pre- and postmenopausal women show divergent MOTS-C responsiveness in glucose uptake assays. 2-[³H]-deoxyglucose uptake increases dose-dependently with MOTS-C in HSMCs from both groups, but the EC50 is approximately 2–3-fold lower in postmenopausal-derived cells, consistent with oestrogen deficiency sensitising muscle to MOTS-C’s insulin-mimetic actions. GLUT4 translocation to the plasma membrane (surface biotinylation assay) increases by ~60% in postmenopausal-derived HSMCs after MOTS-C treatment compared to ~35% in premenopausal-derived cells at matched MOTS-C concentrations — a divergence abolished by pharmacological AMPK restoration with AICAR, indicating the sensitisation is AMPK-state dependent rather than receptor-level.

Perimenopausal Metabolic Syndrome: MOTS-C as a Research Framework

The perimenopausal transition is accompanied by a characteristic shift in body composition — central visceral adiposity accumulation, reduced lean mass, impaired glucose tolerance, and dyslipidaemia — that is not fully explained by oestrogen withdrawal alone. The concurrent fall in MOTS-C provides a mechanistic framework for this transition: declining E2 → reduced ERβ-driven mitochondrial biogenesis → lower MOTS-C production → reduced AMPK-GLUT4 insulin sensitivity + impaired β-oxidation → visceral fat deposition and insulin resistance.

In OVX C57BL/6 mouse models, s.c. MOTS-C administration (5 mg/kg/day, 4 weeks) during the oestrogen-deficient state partially but significantly reverses the metabolic phenotype: EchoMRI body composition shows a 15–22% reduction in fat mass with preservation of lean mass compared to OVX vehicle controls, fasting insulin and HOMA-IR improve by 25–35%, and liver steatosis (H&E Oil Red O, hepatic TG) is reduced. The improvement in EchoMRI fat mass is most pronounced in visceral depots (epididymal/mesenteric in males, perigonadal/mesenteric in OVX females), consistent with AMPK’s preferential effect on visceral adipocyte lipogenesis.

Adipokine Profiles

Multiplex adipokine panels (Luminex or equivalent) in MOTS-C-treated OVX mice reveal restoration of the adiponectin:leptin ratio toward sham-operated values — adiponectin rising (reflecting improved adipocyte metabolic health) and leptin falling (reflecting reduced fat mass). Resistin and chemerin, pro-inflammatory adipokines elevated in oestrogen-deficient states, fall with MOTS-C treatment in proportion to the visceral fat reduction. These adipokine changes support improved hepatic insulin sensitivity via the adiponectin → AdipoR1/R2 → AMPK hepatic axis.

MOTS-C and Female Bone Biology

Postmenopausal bone loss is driven by accelerated osteoclastogenesis secondary to E2 deficiency — elevated RANKL:OPG ratio in osteoblasts, increased RANKL from T-cells, and reduced OPG production. MOTS-C exerts anabolic effects on the skeleton via AMPK-dependent osteoblast function, and its decline with oestrogen withdrawal may contribute to the acceleration of postmenopausal osteoporosis beyond what E2 deficiency alone predicts.

Primary calvarial osteoblasts from OVX mice show reduced ALP activity, impaired mineralisation (Alizarin Red S), and lower RUNX2/OSX mRNA compared to sham controls. MOTS-C rescue (100 nM in vitro) restores these parameters to sham levels via AMPK-α Thr-172 → GSK-3β Ser-9 → Wnt/β-catenin nuclear translocation. The RANKL:OPG mRNA ratio in MOTS-C-treated OVX osteoblasts shifts toward OPG dominance (RANKL:OPG falling from ~2.5:1 to ~1.1:1 by qPCR), reducing the osteoclastogenic stimulus.

In the OVX micro-CT model (12-week OVX C57BL/6), MOTS-C co-administration (s.c. 5 mg/kg) from weeks 4–12 post-OVX produces measurable improvements in trabecular parameters: BV/TV (+18–25% vs OVX vehicle), Tb.N (+15%), Tb.Th (+10%), and SMI reduction (indicating more plate-like vs rod-like trabeculae). Cortical thickness (Ct.Th) improvements are smaller but significant at the femoral mid-shaft. These skeletal effects require concurrent AMPK activity (compound C co-treatment abolishes protection), and are not replicated by PPT (ERα agonist), confirming MOTS-C acts independently of direct ER activation.

Cardiovascular Research: Female-Specific MOTS-C Cardioprotection

Premenopausal women have lower cardiovascular disease (CVD) risk than age-matched men — a protection largely lost after menopause. MOTS-C’s cardiovascular biology intersects female-specific risk in several ways. Endothelial AMPK activation by MOTS-C promotes eNOS Ser-1177 phosphorylation and NO production — a canonical atheroprotective mechanism. In oestrogen-replete endothelium, E2 itself phosphorylates eNOS via PI3K-Akt-Ser-1177, making the combined E2 + MOTS-C input partially redundant. After oestrogen withdrawal, MOTS-C becomes a more critical maintainer of endothelial NO bioavailability.

In OVX ApoE⁻/⁻ atherosclerosis-prone mice fed a Western diet, MOTS-C treatment (15 µg/day s.c., 12 weeks) reduces en face Oil Red O plaque area by approximately 30% compared to OVX vehicle, associated with reduced ICAM-1/VCAM-1 aortic endothelial expression, lower circulating LDL-C, and improved HDL-C — all consistent with AMPK-driven lipid clearance and anti-inflammatory endothelial reprogramming. The plaque reduction in OVX mice treated with MOTS-C is comparable in absolute terms to that in OVX mice given low-dose E2, suggesting MOTS-C partially compensates for oestrogen-mediated atheroprotection.

Mitochondrial Function in Female Cardiac Tissue

Sex differences in cardiac mitochondria are well-established: female hearts have higher mitochondrial density, greater respiratory capacity, and lower basal ROS production than male hearts under non-pathological conditions — differences attributable partly to ERβ-driven mitochondrial gene expression. After oestrogen withdrawal, female cardiac mitochondria shift toward a male-like phenotype: reduced Complex I/III activity, lower Seahorse XF OCR (oxygen consumption rate) and spare respiratory capacity (SRC), and increased 4-HNE protein adducts (lipid peroxidation marker). MOTS-C (10 nM, 48h) in isolated adult female mouse cardiomyocytes from OVX animals restores OCR and SRC toward sham values via AMPK-ULK1-mitophagy clearance of damaged mitochondria and PGC-1α-NRF1-TFAM biogenesis induction.

MOTS-C and Female Exercise Biology

Exercise increases circulating MOTS-C in both sexes, with the magnitude of increase proportional to exercise intensity and the baseline mitochondrial density of active muscle. In postmenopausal women performing acute aerobic exercise (70% VO₂max, 45 min), MOTS-C plasma increases are blunted compared to premenopausal women at matched relative intensity — consistent with the lower mitochondrial density and reduced MOTS-C transcriptional baseline in oestrogen-deficient muscle. Resistance exercise produces smaller acute MOTS-C increases than aerobic exercise in both groups, though chronic resistance training does increase resting MOTS-C modestly over 12 weeks (presumably via cumulative mitochondrial biogenesis).

In OVX mouse voluntary wheel-running models, MOTS-C supplementation during the oestrogen-deficient period prevents the reduction in exercise capacity (peak running speed on progressive treadmill test) seen in OVX vehicle controls, suggesting that restoring MOTS-C to premenopausal-equivalent levels compensates for the exercise-sensitising role of oestrogen in muscle mitochondrial function. MOTS-C + exercise combination outperforms either alone in improving HOMA-IR and body composition in OVX mice — an additive interaction at the level of skeletal muscle AMPK-GLUT4 signalling.

MOTS-C and Polycystic Ovary Syndrome Research

Polycystic ovary syndrome (PCOS) is characterised by hyperandrogenaemia, ovulatory dysfunction, and insulin resistance — the latter driven partly by impaired skeletal muscle mitochondrial function. MOTS-C levels in PCOS patients are lower than in BMI-matched controls in several observational studies, and negatively correlate with fasting insulin and HOMA-IR. The mechanistic hypothesis is that hyperandrogenaemia suppresses ERβ-mediated mitochondrial biogenesis (testosterone partially antagonises ERβ transactivation of TFAM in the presence of low E2), reducing MOTS-C output and worsening the insulin resistance that is already promoted by androgen receptor signalling in muscle.

In DHT-treated female rats (PCOS model: SC DHT implant from prepuberty), MOTS-C administration reduces fasting insulin, improves oestrous cyclicity (vaginal smear), and reduces ovarian cystic follicle count — a constellation consistent with partial metabolic restoration reducing the hyperinsulinaemia-driven LH hyperstimulation that sustains androgen excess. These findings are preliminary but mechanistically plausible given MOTS-C’s AMPK-insulin sensitising biology in female reproductive tissue.

Research Endpoints for Female-Focused MOTS-C Studies

Studies examining MOTS-C in female biology require sex-stratified design from the outset. Critical methodological considerations include: oestrous cycle staging (vaginal cytology: proestrus/oestrus/metoestrus/dioestrus) when using intact female mice to control for within-individual E2 variation; OVX validation by uterine weight atrophy at endpoint; plasma E2 and FSH by ELISA or LC-MS to confirm menopausal status in human samples; and MOTS-C quantification by validated sandwich ELISA with sex-appropriate reference ranges.

For in vitro work, primary cells should be sourced from female donors and passage-matched, with the donor’s hormonal status recorded. ERβ knockdown (siRNA or CRISPR) or pharmacological antagonism (PHTPP) controls are essential to establish E2–ERβ dependence of any MOTS-C regulation finding. AMPK-α1/α2 isoform specificity (compound C plus isoform-selective siRNA) should be assessed given that isoform ratios differ between female skeletal muscle and adipose tissue.

Summary

MOTS-C occupies a genuinely sex-dimorphic position in mitochondrial peptide biology. Its regulation by E2–ERβ–PGC-1α–TFAM creates a direct link between female reproductive status and MOTS-C output, explaining why the perimenopausal decline in MOTS-C parallels the metabolic deterioration of the menopausal transition. Research frameworks centred on MOTS-C restoration in oestrogen-deficient states — whether pharmacological, dietary, or exercise-based — represent a productive translational direction for postmenopausal metabolic syndrome, osteoporosis, and cardiovascular risk. PCOS provides a second female-specific context where MOTS-C biology intersects reproductive and metabolic dysfunction through the androgen–ERβ–mitochondria axis.